Why JAGX was halted on Sep 23 2026: fda fee waivers
JAGX-51.7%on Wed Sep 23 2026
Jaguar Health, Inc. was down 51.7% on the day at $16.66, ranked #149 on 7.2× its usual five-minute volume, when TapeRank recorded this trading halt at 09:31 ET during regular hours when it was halted. TapeRank recorded 2 events for JAGX that day, between 04:08 and 09:31 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 04:08 ETMOVER · PRE-MARKET
$27.44 · ▼ 20.4% ON THE DAY · 214× 5M RVOL · RANK #5
STRETCHEDCONFIDENCE5/5JAGX is up 13.1% at $38.97 after an earlier roughly 1,190% surge tied to FDA waivers of 2027 user fees for Mytesi and Canalevia. The waivers reduce regulatory costs but provide no quantified revenue or clinical breakthrough, making the extreme cumulative move far larger than the news supports.
WHYA fee waiver is a modest cost-saving catalyst, while the stock has risen about 1,200% and remains up 13.1%, so the move is dramatically larger than the news.ANALYZED 04:01 ET · 7 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 04:08 ET
LAST27.44DAY▼ 20.4%5 MIN▼ 26.89%5M RVOL214×5M $VOL$5.0MFLOAT—RANK#5SESSIONPRE-MARKETVWAP37.44HOD43.95LOD28.68OR HIGH—OR LOW—PREV CLOSE34.46PM HIGH43.95PM LOW28.68GAP▼ 15.93% (indicated)— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 09:31 ETHALT · REGULAR
HALTED AT $16.66 · ▼ 51.7% ON THE DAY · 7.2× 5M RVOL · RANK #149
STRETCHEDCONFIDENCE5/5JAGX is down 52.8% pre-market to $16.25 after previously surging roughly 1,190% on FDA fee waivers for two existing therapies. The waivers reduce regulatory costs but do not represent approval, materially new revenue, or a fundamental change large enough to support the prior move, so the current reversal is consistent with profit-taking after an overstretched reaction.
WHYA 1,190% prior surge and 52.8% reversal are vastly larger than the economic significance of fee waivers on existing drugs.ANALYZED 09:08 ET · 23 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:31 ET
LAST16.66DAY▼ 51.7%5 MIN▲ 1.96%5M RVOL7.2×5M $VOL$2.0MFLOAT—RANK#149SESSIONREGULARVWAP19.03HOD43.95LOD12.35OR HIGH16.66OR LOW14.64PREV CLOSE34.46PM HIGH43.95PM LOW12.35GAP▼ 55.22%
THE SESSION
- 09:30 ETOpened at $15.43, -55.2% on the previous close of $34.46
- 09:30 ETHalted (LUDP); resumed 09:40 ET, after 10 minutes
- 09:43 ETRegular-session high, $19.46
- 10:24 ETHalted (LUDP); resumed 10:29 ET, after 5 minutes
- 12:35 ETHalted (LUDP); resumed 12:40 ET, after 5 minutes
- 12:44 ETHalted (LUDP); resumed 12:44 ET, after 1 minute
- 12:58 ETRegular-session low, $8.50
- 15:59 ETLast trade of the regular session, $9.01, -73.9% on the previous close of $34.46
- Volume: 6.7M shares in regular hours, 4.6M before the open
JAGX opened at $15.43 after its earlier surge tied to FDA waivers of 2027 user fees for Mytesi and Canalevia, which reduced regulatory costs but did not provide new approval or quantified revenue. TapeRank tied the reversal to that stretched move, with the stock reaching $19.46 at 09:43 before four LUDP halts interrupted trading; it then fell to a $8.50 low at 12:58 and ended at $9.01, down 73.9% from the previous close.
WRITTEN THU OCT 15 2026 17:54 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- TUE 23:29 ETJaguar Health Stock Surged 1200% on Tuesday: Here's Why JAGX Stock Is Trending After HoursBenzinga
- TUE 21:18 ETJaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars TodayBenzinga
- TUE 09:07 ETFDA Grants Jaguar Health Family Company Napo Pharma's Request For Waiver Of Fee Associated With PDUFA For Mytesi For 2027 Fiscal YearBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list